Loading organizations...

CinCor Pharma is a technology company.
CinCor Pharma has raised $415.0M across 3 funding rounds.
Key people at CinCor Pharma.
CinCor Pharma was founded in 2018 by Catherine Pearce (COO and Co-Founder).
CinCor Pharma has raised $415.0M in total across 3 funding rounds.
CinCor Pharma is a clinical-stage biopharmaceutical company developing novel therapeutics for cardio-renal diseases, with a primary focus on hypertension. Its lead candidate, CIN-107, is a highly selective, oral small molecule inhibitor designed to target aldosterone synthase. This therapeutic approach aims to directly inhibit the enzyme responsible for aldosterone synthesis, offering a differentiated mechanism for treating high blood pressure and associated conditions.
The company was co-founded by Dr. Catherine Pearce, who also serves as Chief Operating Officer, and began operations around May 2019. CinCor Pharma emerged from the insight that despite numerous available treatments, a significant number of hypertensive patients do not achieve adequate blood pressure control. This foundational understanding drove the development of a targeted therapy to address these persistent unmet medical needs.
CinCor Pharma primarily serves patients suffering from hypertension, particularly those for whom current treatments are insufficient. The company envisions providing an improved and effective solution for these individuals, ultimately aiming to benefit a broader population impacted by uncontrolled blood pressure and various cardio-renal disorders. Its mission is centered on advancing promising clinical candidates to address critical gaps in therapeutic options.
CinCor Pharma was founded in 2018 by Catherine Pearce (COO and Co-Founder).
CinCor Pharma has raised $415.0M in total across 3 funding rounds.
CinCor Pharma's investors include Jason Pitts, ARCH Venture Partners, Keno Gutierrez, Soffinova Partners, Sofinnova Investments, Third Rock Ventures, Westlake Village BioPartners, David Morris, Heather Preston, Adage Capital Management, BVF Partners, CinCor Pharma.
Key people at CinCor Pharma.
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cardiovascular, metabolic, kidney diseases, and hypertension, with its lead candidate CIN-107 (baxdrostat), a selective oral inhibitor of aldosterone synthase.[1][2][3] The company serves patients with uncontrolled or treatment-resistant hypertension, primary aldosteronism (PA), and complications of chronic kidney disease (CKD), addressing unmet needs in cardio-renal diseases through a differentiated mechanism that directly inhibits aldosterone production for potentially improved efficacy over existing therapies.[1][2] Founded in 2018 and headquartered in Waltham, MA, CinCor advanced CIN-107 through key Phase 2 and 3 trials (e.g., BrigHtn, HALO, BaxHTN), achieving positive topline data published in the New England Journal of Medicine, before its acquisition by AstraZeneca, marking a successful exit for investors like Sofinnova Partners.[1]
CinCor Pharma was founded in 2018 by Jon Isaacsohn, M.D. and Catherine Pearce, DHSc, MBA, both experienced in biopharma development, with a focus on advancing clinical candidates in cardiovascular and renal diseases.[1][4] The idea emerged from the need for novel therapies targeting aldosterone synthase to treat hypertension and related conditions more effectively, leading to the development of CIN-107.[2] Early traction included positive Phase 2 BrigHtn trial results in treatment-resistant hypertension, published in a top medical journal, and progression to Phase 3 trials like BaxHTN and HALO, which met primary and secondary endpoints.[1]
CinCor rode the trend of precision medicine in cardio-renal diseases, where hypertension affects over 1 billion people globally and treatment resistance remains a major challenge amid rising CKD and metabolic disorders.[2][3] Timing was ideal post-2018, with growing demand for aldosterone-targeted therapies amid failures in broader antihypertensive markets, bolstered by supportive trial data and NEJM publication that elevated its profile.[1] Market forces like biopharma M&A activity favored CinCor, leading to its AstraZeneca acquisition, which integrates its assets into a major player's portfolio and influences the ecosystem by accelerating baxdrostat's commercialization while highlighting investor interest in novel enzyme inhibitors.[1]
Post-acquisition by AstraZeneca, CinCor's pipeline—led by baxdrostat—will likely advance toward regulatory approval and broader cardio-renal indications, leveraging AstraZeneca's resources for global reach.[1] Trends like personalized hypertension treatments and aldosterone pathway innovations will shape its trajectory, potentially expanding to CKD and PA markets. Its influence evolves from a standalone innovator to an integrated asset, reinforcing biopharma's shift toward targeted acquisitions and underscoring the value of clinical-stage biotech in addressing unmet needs in chronic diseases—echoing its origins in advancing promising candidates to real-world impact.[1][2]
CinCor Pharma has raised $415.0M across 3 funding rounds. Most recently, it raised $225.0M Other Equity in August 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2021 | CinCor Pharma | $140.0M Series B | Jason Pitts | ARCH Venture Partners, Keno Gutierrez, Soffinova Partners, Sofinnova Investments, Third Rock Ventures, Westlake Village BioPartners, David Morris, Heather Preston, Adage Capital Management, BVF Partners, CinRx Pharma, Lilly Asia Ventures, Omega Funds, Perceptive Advisors, Rock Springs Capital, RTW Investments, Sixty Degree Capital |
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 11, 2022 | $225.0M Other Equity | ||
| Oct 1, 2021 | $140.0M Series B | Jason Pitts | ARCH Venture Partners, Keno Gutierrez, Soffinova Partners, Sofinnova Investments, Third Rock Ventures, Westlake Village BioPartners, David Morris, Heather Preston, Adage Capital Management, BVF Partners, CinCor Pharma, CinRx Pharma, Lilly Asia Ventures, Omega Funds, Perceptive Advisors, Rock Springs Capital, RTW Investments, Sixty Degree Capital |
| May 1, 2019 | $50.0M Series A | Sofinnova Investments | ARCH Venture Partners, Keno Gutierrez, Soffinova Partners, Third Rock Ventures, Westlake Village BioPartners, David Morris, Heather Preston, David Allison |